Bio-Rad Laboratories, Inc. (NYSE:BIO) to Post Q1 2025 Earnings of $2.39 Per Share, Zacks Research Forecasts

Bio-Rad Laboratories, Inc. (NYSE:BIO) – Investment analysts at Zacks Research upped their Q1 2025 earnings estimates for Bio-Rad Laboratories in a research report issued to clients and investors on Monday, April 15th. Zacks Research analyst R. Anand now forecasts that the medical research company will earn $2.39 per share for the quarter, up from their previous forecast of $2.35. The consensus estimate for Bio-Rad Laboratories’ current full-year earnings is $10.41 per share. Zacks Research also issued estimates for Bio-Rad Laboratories’ Q3 2025 earnings at $3.83 EPS.

Bio-Rad Laboratories (NYSE:BIO) last issued its earnings results on Thursday, February 15th. The medical research company reported $3.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.93 by $0.17. Bio-Rad Laboratories had a negative net margin of 23.86% and a positive return on equity of 3.90%. The business had revenue of $681.18 million for the quarter, compared to analyst estimates of $685.00 million. During the same period in the prior year, the firm earned $3.31 earnings per share. Bio-Rad Laboratories’s revenue was down 6.7% on a year-over-year basis.

A number of other research analysts have also weighed in on the stock. UBS Group raised their price objective on shares of Bio-Rad Laboratories from $395.00 to $420.00 and gave the company a “buy” rating in a research note on Friday, February 16th. StockNews.com lowered shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Friday, April 5th. Citigroup lowered shares of Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $400.00 to $365.00 in a research note on Wednesday, April 3rd. Finally, Royal Bank of Canada dropped their price target on shares of Bio-Rad Laboratories from $484.00 to $480.00 and set an “outperform” rating on the stock in a research report on Friday, February 16th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $468.00.

Bio-Rad Laboratories Stock Performance

Shares of Bio-Rad Laboratories stock traded down $1.89 during trading hours on Wednesday, reaching $290.86. The company’s stock had a trading volume of 214,091 shares, compared to its average volume of 199,335. Bio-Rad Laboratories has a one year low of $261.59 and a one year high of $489.36. The stock’s fifty day simple moving average is $332.35 and its two-hundred day simple moving average is $321.22. The company has a quick ratio of 4.34, a current ratio of 5.83 and a debt-to-equity ratio of 0.14.

Insider Buying and Selling

In related news, EVP Michael Crowley sold 3,000 shares of the firm’s stock in a transaction dated Tuesday, February 27th. The shares were sold at an average price of $336.00, for a total transaction of $1,008,000.00. Following the completion of the sale, the executive vice president now owns 6,942 shares in the company, valued at $2,332,512. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 17.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Bio-Rad Laboratories

Several large investors have recently modified their holdings of BIO. Quarry LP purchased a new position in shares of Bio-Rad Laboratories in the fourth quarter worth about $27,000. Farther Finance Advisors LLC increased its stake in shares of Bio-Rad Laboratories by 42.3% in the second quarter. Farther Finance Advisors LLC now owns 101 shares of the medical research company’s stock worth $38,000 after purchasing an additional 30 shares in the last quarter. Sound Income Strategies LLC purchased a new position in Bio-Rad Laboratories during the first quarter valued at approximately $38,000. Gladius Capital Management LP grew its stake in Bio-Rad Laboratories by 65.8% during the fourth quarter. Gladius Capital Management LP now owns 121 shares of the medical research company’s stock valued at $39,000 after acquiring an additional 48 shares in the last quarter. Finally, Principal Securities Inc. purchased a new position in Bio-Rad Laboratories during the fourth quarter valued at approximately $41,000. Hedge funds and other institutional investors own 65.24% of the company’s stock.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.